JAZZ PHARMACEUTICALS INC

Form 4

January 13, 2012

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * COLELLA SAMUEL D

2. Issuer Name and Ticker or Trading

Symbol

JAZZ PHARMACEUTICALS INC

(Check all applicable)

5. Relationship of Reporting Person(s) to

[JAZZ]

(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)

Officer (give title

Issuer

10% Owner Other (specify

01/11/2012

C/O VERSANT VENTURES, 3000 SAND HILL ROAD, BLDG 4 STE 210

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X__ Director

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

MENLO PARK, CA 94025

| (City) | (State) | (Zip) Tabl | e I - Non-D | Derivative S | Securi | ities Acqu | ired, Disposed of | f, or Beneficial | ly Owned |
|--------------------------------------|--------------------------------------|---|-----------------|---|------------------------------|----------------|--|---|---|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Code (Instr. 8) | 4. Securition(A) or Dis (Instr. 3, 4 | sposed and 5 (A) or | of (D) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Common Stock | 01/11/2012 | | Code V M | Amount 10,000 | (D) | Price \$ 12.75 | 10,000 | D | |
| Common Stock | 01/11/2012 | | F(1) | 2,623 | D | \$ 48.6 | 7,377 | D | |
| Common Stock | 01/11/2012 | | M | 10,000 | A | \$ 7.84 | 17,377 | D | |
| Common Stock | 01/11/2012 | | F(1) | 1,613 | D | \$ 48.6 | 15,764 | D | |
| | 01/11/2012 | | M | 10,000 | A | \$ 6.33 | 25,764 | D | |

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form 4

| Common Stock | | | | | | | | | | |
|--|------------|------|--------|---|-------------|-----------|---|---|--|--|
| Common Stock | 01/11/2012 | F(1) | 1,302 | D | \$ 48.6 | 24,462 | D | | | |
| Common Stock | 01/11/2012 | M | 12,500 | A | \$ 8.23 | 36,962 | D | | | |
| Common Stock | 01/11/2012 | F(1) | 2,116 | D | \$ 48.6 | 34,846 | D | | | |
| Common Stock | 01/11/2012 | M | 12,500 | A | \$ 34.99 | 47,346 | D | | | |
| Common Stock | 01/11/2012 | F(1) | 8,999 | D | \$ 48.6 | 38,347 | D | | | |
| Common Stock | | | | | | 1,488,676 | I | By Versant Venture Capital II, L.P. (2) | | |
| Common Stock | | | | | | 28,260 | I | By Versant Affiliates Fund II-A, L.P. (3) | | |
| Common Stock | | | | | | 13,247 | I | By Versant Side Fund II, L.P. (4) | | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of SEC 1474 | | | | | | | | | | |

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of | 2. | 3. Transaction Date | 3A. Deemed | 4. | 5. Number of | 6. Date Exer | cisable and | /. Title and | Amount of |
|-------------|-------------|---------------------|--------------------|------------|----------------|--------------|-------------|---------------|------------|
| Derivative | Conversion | (Month/Day/Year) | Execution Date, if | Transactio | orDerivative | Expiration D | ate | Underlying | Securities |
| Security | or Exercise | | any | Code | Securities | (Month/Day/ | Year) | (Instr. 3 and | 4) |
| (Instr. 3) | Price of | | (Month/Day/Year) | (Instr. 8) | Acquired (A) | | | | |
| | Derivative | | • | | or Disposed of | | | | |
| | Security | | | | (D) | | | | |
| | - | | | | (Instr. 3, 4, | | | | |
| | | | | | and 5) | | | | |
| | | | | | | | | | Amount |
| | | | | | | Date | Expiration | | or |
| | | | | | | Exercisable | Date | Title | Number |
| | | | | Code V | (A) (D) | | | | of Shares |
| | | | | | | | | | |

(9-02)

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form 4

| (| Option (right to buy) | \$ 12.75 | 01/11/2012 | M | 10,000 | (5) | 08/15/2017 | Common Stock | 10,000 |
|---|-----------------------------|----------|------------|---|--------|------------|------------|-----------------|--------|
| (| Option (right to buy) | \$ 7.84 | 01/11/2012 | M | 10,000 | <u>(6)</u> | 08/15/2018 | Common Stock | 10,000 |
| (| Option (right to buy) | \$ 6.33 | 01/11/2012 | M | 10,000 | <u>(7)</u> | 08/16/2019 | Common Stock | 10,000 |
| (| Option (right to buy) | \$ 8.23 | 01/11/2012 | M | 12,500 | (8) | 08/25/2020 | Common Stock | 12,500 |
| (| Option (right to buy) | \$ 34.99 | 01/11/2012 | M | 12,500 | (9)(10) | 11/04/2021 | Common Stock | 12,500 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|---|---------------|-----------|---------|-------|--|--|--|
| | Director | 10% Owner | Officer | Other | | | |
| COLELLA SAMUEL D C/O VERSANT VENTURES 3000 SAND HILL ROAD, BLDG 4 STE 210 MENLO PARK, CA 94025 | X | | | | | | |

Signatures

/s/ Carol A. Gamble as attorney-in-fact for Samuel D. Colella 01/13/2012

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents shares withheld by the Issuer for cashless exercise of nonstatutory stock options solely to cover exercise price.
- The shares are owned by Versant Venture Capital II, L.P. Versant Ventures II, LLC is the general partner of Versant Venture Capital II, L.P. The Reporting Person is a managing member of Versant Ventures II, LLC and shares voting and investment power over the shares held by Versant Venture Capital II, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Versant Venture Capital II, L.P. except to the extent of his proportionate pecuniary interest therein.
- The shares are owned by Versant Affiliates Fund II-A, L.P. Versant Ventures II, LLC is the general partner of Versant Affiliates Fund II-A, L.P. The Reporting Person is a managing member of Versant Ventures II, LLC and shares voting and investment power over the shares held by Versant Affiliates Fund II-A, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Versant Affiliates Fund II-A, L.P. except to the extent of his proportionate pecuniary interest therein.
- The shares are owned by Versant Side Fund II, L.P. Versant Ventures II, LLC is the general partner of Versant Side Fund II, L.P. The

 Reporting Person is a managing member of Versant Ventures II, LLC and shares voting and investment power over the shares held by

 Versant Side Fund II, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Versant Side Fund II, L.P. except to the extent of his proportionate pecuniary interest therein.

Reporting Owners 3

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form 4

- (5) This nonstatutory stock option vested in 12 equal monthly installments from August 15, 2007.
- (6) This nonstatutory stock option vested in 12 equal monthly installments from August 15, 2008.
- (7) This nonstatutory stock option vested in 12 equal monthly installments from August 17, 2009.
- (8) This nonstatutory stock option vested in 12 equal monthly installments from August 15, 2010.
- (9) This nonstatutory stock option has a vesting schedule of 100% vesting in 12 equal monthly installments from August 15, 2011.
- On October 24, 2011, the Board of Directors of the Issuer approved the full vesting of unvested nonstatutory stock options held by the
- (10) Issuer's officers and non-employee directors, including the Reporting Person. Such vesting acceleration became effective on December 13, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.